Overview

PATHOGEN-SPECIFIC IMMUNOMODULATORS

1. INTRAVENOUS IMMUNOGLOBULIN (IVIG) (UPDATED)
2. CONVALESCENT PLASMA (UPDATED)
3. HYPERIMMUNE GLOBULIN (UPDATED)

NON-PATHOGEN-SPECIFIC IMMUNOMODULATORS

1. ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS
2. ALPHA 1 ADRENERGIC RECEPTOR ANTAGONISTS
3. ANTIVIRALS
1. FAVIPIRAVIR / T-705/ FAVIPIRA/ FAVILAVIR (UPDATED)
2. LOPINAVIR/RITONAVIR (LPV/r) (UPDATED)
3. OSELTAMIVIR (UPDATED)
4. REMDESIVIR/ RDV/ GS-5734 (UPDATED)
5. RIBAVIRIN/RBV (UPDATED)
6. UMIFENOVIR (ARBIDOL) (UPDATED)
4. ASPIRIN
5. AZATHIOPRINE
6. AZITHROMYCIN (UPDATED)
7. BCG VACCINE (UPDATED)
8. CALCINEURIN INHIBITORS
1. CYCLOSPORINE
2. TACROLIMUS (UPDATED)
9. COLCHICINE
10. CORTICOSTEROIDS (UPDATED)
11. HYDROXYCHLOROQUINE (HCQ) AND CHLOROQUINE (CQ) (UPDATED)
12. INOSINE PRANOBEX
13. INTERFERON AND INTERFERON INHIBITORS (UPDATED)
14. TARGETED MONOCLONAL ANTIBODIES
1. ANTI-GM-CSF or GM-CSF INHIBITORS (UPDATED)
2. ANTI-INTERLEUKIN-1 (IL–1) or IL–1 INHIBITORS (UPDATED)
3. ANTI-INTERLEUKIN 6 (IL–6) or IL–6 INHIBITORS (UPDATED)
4. ANTI-TNF or TNF INHIBITORS (UPDATED)
5. CCR5 INHIBITOR (LERONLIMAB)
6. INTERLEUKIN 2
7. JAK 1 & 2 INHIBITORS (UPDATED)
15. MESENCHYMAL STEM (STROMAL) CELLS (UPDATED)
16. RELEASE ACTIVE ANTIBODIES TO HUMAN INTERFERON GAMMA
17. STATINS (UPDATED)
18. SUPPLEMENTS
1. VITAMIN C AND QUERCETIN (UPDATED)
2. VITAMIN D
3. ZINC
4. MELATONIN (UPDATED)
5. PROBIOTICS
6. OMEGA 3 FATTY ACID AND DHA

NEW IMMUNOMODULATORS REVIEWED FOR THE 3RD VERSION

1. ANTI-COAGULANTS (HEPARIN AND ITS DERIVATIVES)
2. ANTIHISTAMINES
3. BETA-GLUCAN
4. H2 RECEPTOR BLOCKERS (FAMOTIDINE)
5. MYCOPHENOLATE MOFETIL
6. VIRGIN COCONUT OIL (LAURIC ACID)

CONCLUDING REMARKS

1. AUTHORS & THEIR ACADEMIC POSITION OR HOSPITAL AFFILIATION
2. AVAILABILITY OF THE IMMUNOMODULATORS IN THE PHILIPPINES
3. TABLES OF PUBLISHED STUDIES